XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statement of Cash Flows
$ in Thousands
 3 Months Ended 10 Months Ended 12 Months Ended
Mar. 31, 2024
EUR (€)
shares
Mar. 31, 2024
USD ($)
shares
Mar. 31, 2023
EUR (€)
shares
Mar. 31, 2023
USD ($)
shares
Dec. 31, 2022
EUR (€)
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2023
EUR (€)
shares
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
EUR (€)
shares
Dec. 31, 2022
USD ($)
shares
Cash flows from operating activities:                    
Net loss   $ (3,374)   $ (3,905)       $ (56,347)   $ (52,629)
Adjustments to net loss:                    
Depreciation and amortization   74   942       2,484   2,629
Share based compensation   10   654       1,577   797
Asset impairment   898   0            
Stock-based compensation   10   654       1,591   3,404
Goodwill impairment               23,372   25,452
Other asset impairments               20,840   783
Changes in fair value of investments and liabilities   607   883       (1,991)   593
Bad debt expense   47   29       801   1,607
Loss on disposal of discontinued operations               3,132   0
Interest expense (income)   22   23       94   (56)
Interest paid   (22)   (23)       (94)   (4)
Income tax benefit   128   (66)       (1,617)   (1,538)
Net income (loss) to cash provided by (Used in) operating activities   (1,610)   (1,463)       (7,735)   (19,759)
Net change in non-cash working capital:                    
Trade and other receivables   (292)   91       1,522   143
Inventory   (738)   (113)       576   1,219
Prepaid expenses and other assets   268   (920)       (419)   1,372
Trade payables and accrued liabilities   1,032   (1,919)       (2,340)   1,090
Net cash provided by (used in) operating activities   (1,340)   (4,324)       (8,396)   (15,935)
Cash flows from investing activities:                    
Purchases of property, plant and equipment and intangible assets   (88)   (102)       (163)   (1,294)
Net cash on disposal               (71)   0
Business and asset acquisitions, net of cash acquired               0   (14,508)
Net cash used in investing activities   (88)   (102)       (234)   (15,802)
Cash flows from financing activities:                    
Equity issue costs               (396)   (520)
Exercise of warrants and options               0   187
Common shares repurchased               0   (255)
Proceeds from issuance of debt   3,078   0       995   197
Proceeds from issuance of shares               2,738   5,000
Loan repayments   (1,890)   (19)       (187)   (196)
Net cash provided by (used in) financing activities   1,188   (19)       3,150   4,413
Cash included in assets held for sale   0   (203)   $ (602)   0   (602)
Change in cash during the period   (194)   (4,278)       (4,550)   (28,079)
Cash and restricted cash at beginning of period   4,385   9,537       9,537   37,616
Effect of exchange rate on changes on cash   46   167       930   (755)
Cash and restricted cash at end of period   $ 4,191   $ 5,056   $ 9,537   4,385   9,537
Supplemental disclosure of non-cash investing and financing activities                    
Assets acquired for contingent consideration | shares 0 0 303 303            
Common shares issued for business combinations               $ 0   $ 24,712
Common shares issued for other agreements | shares 55 55 95 95     95 95 1,470 1,470
Option cancellations reclassified to equity   $ 303   $ 765       $ 5,352   $ 451
Operating lease additions to right of use assets | shares 1,247 1,247 97 97     245 245 2,919 2,919
Intangible assets acquired for contingent consideration               $ 194   $ 0
TruHC Pharma GmbH [Member]                    
Cash flows from operating activities:                    
Net loss | € € (105,572)   € (59,893)   € (216,882)   € (371,787)      
Adjustments to net loss:                    
Depreciation and amortization | € 3,742   1,933   9,550   14,675      
Interest expense (income) | € 5,391   0   3,590   13,749      
Operating lease expense net of cash payments | € 3,627   4,903   14,533   17,732      
Net change in non-cash working capital:                    
Amounts receivable | € (2,288)   (2,988)   (18,399)   (495)      
Prepaid expenses and other assets | € 0   0   (20,347)   0      
Trade and amounts payable | € 12,911   44,512   30,061   16,170      
Net cash provided by (used in) operating activities | € (82,189)   (11,533)   (197,894)   (309,956)      
Cash flows from investing activities:                    
Acquisition of equipment | € 0   (197)   (114,325)   (4,737)      
Net cash used in investing activities | € 0   (197)   (114,325)   (4,737)      
Cash flows from financing activities:                    
Proceeds from issuance of debt | € 70,000   0   315,000   313,000      
Proceeds from issuance of shares | € 12,500   0   12,500   0      
Net cash provided by (used in) financing activities | € 82,500   0   327,500   313,000      
Change in cash during the period | € 311   (11,730)   15,281   (1,693)      
Cash and restricted cash at beginning of period | € 13,588   15,281       15,281      
Cash and restricted cash at end of period | € € 13,899   € 3,551   € 15,281   € 13,588   € 15,281  
Supplemental disclosure of non-cash investing and financing activities                    
Operating lease additions to right of use assets | shares         604,294 604,294 0 0